

# Active substances set

**Search phrase:** larotrectinib

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

## Colon and rectum cancer

| | | |
|---|---|---|
| **Larotrectinib** | Larotrectinib as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, - who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and - who have no satisfactory treatment options. | REIMBURSEMENT WITH RESTRICTIONS<br>ESMO |

## Malignant pancreatic cancer

| | | |
|---|---|---|
| **Larotrectinib** | Larotrectinib as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, - who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and - who have no satisfactory treatment options. | REIMBURSEMENT WITH RESTRICTIONS<br>ESMO |

## Tracheal, bronchus, and lung cancer

| | | |
|---|---|---|
| **Larotrectinib** | Larotrectinib as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, - who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and - who have no satisfactory treatment options. | REIMBURSEMENT WITH RESTRICTIONS<br>ESMO |